Treatment of human breast cancer with dexosomes resulted in incorporation into tumors and subsequent expression of dexosome immunostimulatory molecules (e.g., CD86, CD81, MHCI/II + tumor antigen) on tumor cell surfaces, thus boosting tumor immunogenicity and T-cell engagement (170). This evidence concerns the gene CD86 and neoplasm.